AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4091995
Drug: Dextropropoxyphene/paracetamol mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg) + Ethanol (0.8 g kg‐1)
Trial: 4091995
Drug: Ethanol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.8 g kg‐1)
Trial: 4091995
Drug: Meptazinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (200 mg) + Ethanol (0.8 g kg‐1)
Trial: 18815396
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (0.9 mg per kilogram of body weight)
Trial: 12607792
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg (for patients weighing <= 30 kg)
Trial: 12607792
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (for patients weighing > 30 kg)
Trial: 10372608
Drug: Novel antipsychotics
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antipsychotics (olanzapine, quetiapine, risperidone, sertindole, zotepine)
Trial: 1692948
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sublingual nifedipine
Trial: 28129312
Drug: Glycopyrrolate 1
RxNorm normalized name: glycopyrrolate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 1 mg
Trial: 28129312
Drug: Glycopyrrolate 2
RxNorm normalized name: glycopyrrolate 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 2 mg
Trial: 23845629
Drug: Reduced soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced soybean lipid emulsion (1.0 g/kg/day)
Trial: 23845629
Drug: Standard soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard soybean lipid emulsion (3 g/kg/day)
Trial: 21107317
Drug: Clinical Antipsychotic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Trial: 19120324
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) - StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms
Trial: 17760715
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication (omeprazole, amoxicillin, and clarithromycin)
Trial: 9569998
Drug: ABT-761 (10-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-761 (10-160 mg)
Trial: 2839724
Drug: Susta II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Susta II (12.4-g soy polysaccharide/2000 kcal)
Trial: 2839724
Drug: Enrich (38.5-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrich (38.5-g soy polysaccharide/2000 kcal)
Trial: 1219276
Drug: Idulian (syrup)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idulian (syrup) 2 x 0.5 mg
Trial: 28710329
Drug: Ranolazine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500 mg twice daily, increased to 1,000 mg twice daily after week 2)
Trial: 24156737
Drug: Poor-effort (treatment)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor-effort (treatment) condition
Trial: 18281410
Drug: Fluoxetine (stricter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (stricter definition)
Trial: 16688999
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine for Yiqi Yangyin Quyu (YYQ) and prednisone
Trial: 11600560
Drug: Triglyceride infusion
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride infusion
Trial: 10615946
Drug: Triglyceride infusion
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride infusion with hyperinsulinemic clamp
Trial: 29182037
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.5 mg/kg/day
Trial: 22869571
Drug: TD-1792 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-1792 (2 mg/kg i.v. q24h)
Trial: 22869571
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g i.v. q12h)
Trial: 19927154
Drug: Aliskiren 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 75 mg once daily, increased to 150 mg and then to 300 mg if needed
Trial: 17621602
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 mg kg(‐1) h(‐1)
Trial: 10850585
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy with intravenous ganciclovir and CMV‐hyperimmunoglobulin
Trial: 10850585
Drug: Therapy only
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy only at onset of clinical symptoms (Control)
Trial: 8712444
Drug: Epidural meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural meperidine 12.5 mg
Trial: 8712444
Drug: Epidural meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural meperidine 50 mg
Trial: 8712444
Drug: Epidural meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural meperidine 75 mg
Trial: 8712444
Drug: Epidural meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural meperidine 100 mg
Trial: 6178096
Drug: Ceruletide (CRL)
RxNorm normalized name: ceruletide diethylamine
DrugBank: Ceruletide (DB00403)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceruletide (CRL) at a dose of 2 ng/kg/min
Trial: 26777137
Drug: Simeprevir 100
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 100 mg QD plus PR
Trial: 26777137
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg QD plus PR
Trial: 23983966
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day quercetin
Trial: 23983966
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day quercetin
Trial: 19497244
Drug: Olanzapine 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10, 20, and 40 mg/day (combined)
Trial: 17256809
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (30 units Botox or 90 units Dysport)
Trial: 17256809
Drug: 0.2% Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Nitroglycerin ointment applied three times daily for 8 weeks
Trial: 17256809
Drug: 0.2% Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Nitroglycerin ointment
Trial: 8681500
Drug: Doxazosin (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1-8 mg daily)
Trial: 8681500
Drug: Enalapril (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5-20 mg daily)
Trial: 1977577
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral interferon alpha
Trial: 341964
Drug: Pharmacological doses
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological doses of oxytocin (2.6 mU/minute increasing to 422.4 mU/minute)
Trial: 341964
Drug: Physiological doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological doses of oxytocin (2.6 to 13.2 mU/minute)
Trial: 22191292
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and IV contrast-enhanced MDCT (Gp1)
Trial: 19436042
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 60-min consultation, four weekly appointments with HSCS, and leaflets
Trial: 19436042
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 60-min consultation, four weekly appointments with HSCS, and scheduled appointment at community-based service
Trial: 15313991
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac solution (1.5% wt/wt diclofenac sodium in a carrier containing dimethyl sulfoxide [DMSO])
Trial: 8288743
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral melatonin
Trial: 8288743
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg testosterone propionate i.m. (TP)
Trial: 3086959
Drug: Flunarizine 5
RxNorm normalized name: flunarizine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 5 mg a day for patients over 10 kg, 5 mg every two days for patients under 10 kg (3 months)
Trial: 29091464
Drug: T-LPP supplement
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-LPP supplement
Trial: 24269926
Drug: Methotrexate (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (initial weekly dose of 10 mg, escalating to 25 mg/week) + infliximab (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Trial: 24269926
Drug: Infliximab alone
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab alone (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Trial: 23528365
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel with 1% standardized extract of Sphaeralcea angustifolia
Trial: 23528365
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel with 2% diclofenac
Trial: 18208957
Drug: Telehomecare units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehomecare units with peripheral devices (blood-pressure monitor, weight scale, glucometer, pulse oximeter) installed in patients' homes, used daily for data collection.
Trial: 25484177
Drug: Crocin (30mg/day;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (30mg/day; 15mg BID) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Trial: 25484177
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two placebo tablets per day) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Trial: 23532801
Drug: 5-grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-grass pollen tablets
Trial: 21252745
Drug: Letrozole 10
RxNorm normalized name: letrozole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 10 mg daily for 3 days followed by 800 micrograms of vaginal misoprostol
Trial: 19276230
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion to obtain appropriate FFA concentrations
Trial: 19925723
Drug: Loose larval
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose larval therapy
Trial: 19925723
Drug: Bagged larval
RxNorm normalized name: Bombyx mori larva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bagged larval therapy
Trial: 29188875
Drug: Protein-enriched milk
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-enriched milk (2 x 0.4 L/d)
Trial: 29188875
Drug: Isocaloric carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric carbohydrate drink (2 x 0.4 L/d)
Trial: 24978834
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg)
Trial: 21752522
Drug: Cryptic shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryptic shock group (lactate ≥ 4mmol/L and normotension)
Trial: 15116058
Drug: Gemfibrozil, 600
RxNorm normalized name: Gemfibrozil, 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil, 600 mg, twice daily for 7 days
Trial: 3555944
Drug: Phenobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (100 mg/day for 2 months)
Trial: 29509266
Drug: Control (hip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hip arthroplasty and symptomatic/supportive treatment)
Trial: 27605607
Drug: Cabergoline (D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (D2 agonist)
Trial: 16603132
Drug: Pergolide (D1/D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (D1/D2 agonist)
Trial: 24464452
Drug: Mild/minimal stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild/minimal stimulation protocol of recombinant FSH (rFSH) combined with GnRH antagonist (Group A)
Trial: 24464452
Drug: Standard long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard long protocol of rFSH combined with GnRH agonist (Group B)
Trial: 12699607
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) via videoconferencing (VC)
Trial: 12699607
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) face-to-face (F2F)
Trial: 10720118
Drug: Short-chain fatty
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain fatty acids (SCFA) enema administered twice daily for 3 weeks
Trial: 10720118
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered twice daily for 3 weeks
Trial: 8737132
Drug: Sparfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 6 additional days)
Trial: 8737132
Drug: Sparfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 additional days)
Trial: 8737132
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg once daily for 7 days)
Trial: 1343113
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg dexfenfluramine (dF) twice daily for 3 days prior to glucose infusion; 30 mg dF 90 min before the test.
Trial: 1343113
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dexfenfluramine (dF) before the test.
Trial: 1343113
Drug: dF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dF treatment in obese subjects for one month.
Trial: 1343113
Drug: dF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dF treatment in obese subjects with relative fasting hyperinsulinemia (> 100 pmol/l).
Trial: 1343113
Drug: dF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dF treatment in obese subjects with low fasting plasma insulin (< 100 pmol/l).
Trial: 26700705
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (IFN) 3 × 10(6) IU subcutaneously 3 times a week for 4 weeks and 13-cis-retinoic acid (RA) 40 mg orally daily for 30 days during radiation therapy
Trial: 26700705
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m(2) weekly for 5 weeks during radiation therapy
Trial: 18022679
Drug: Acute nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute nicotine (7 mg patch for 45 min)
Trial: 15901750
Drug: 60% ethanolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% ethanolic extract from the roots of Echinacea angustifolia, 2.5-mL dose
Trial: 12934777
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin 10 mg/d
Trial: 12934777
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine 4 mg/d
Trial: 10822316
Drug: losartan 50-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan 50-100 mg/day (n = 15)
Trial: 10822316
Drug: enalapril 2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 2.5-10 mg/day (n = 14)
Trial: 8867163
Drug: Midazolam 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3.75 mg
Trial: 1518695
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy during clinical trial participation
Trial: 6712393
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tobramycin plus cefamandole
Trial: 6712393
Drug: Interrupted infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interrupted infusion of tobramycin plus cefamandole
Trial: 6860416
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tobramycin
Trial: 6712393
Drug: Interrupted infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interrupted infusion of tobramycin
Trial: 28079236
Drug: CHO-GLN beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-GLN beverage (12.5% maltodextrin plus 15 g GLN)
Trial: 26841875
Drug: interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interpersonal psychotherapy (IPT) + treatment as usual (TAU)
Trial: 22538183
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis brief intervention
Trial: 17563866
Drug: Low-dose, weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, weekly docetaxel chemotherapy
Trial: 11263614
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (Amiodarone)
Trial: 9623426
Drug: Local anaesthetics
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetics (1 ml kg‐1 of a mixture of 0.25% bupivacaine with epinephrine and 1% lidocaine in equal parts)
Trial: 3830246
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 to 0.88 mg daily
Trial: 29289332
Drug: 100μg levothyroxine
RxNorm normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100μg levothyroxine sodium tablet once daily for 6 months
Trial: 29289332
Drug: Tablet dissolution
RxNorm normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet dissolution rate (BP/EP 2014 & USP 2014)
Trial: 23224567
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment followed by balloon treatment (group 1)
Trial: 23224567
Drug: Balloon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon treatment (group 2)
Trial: 12928051
Drug: ‐174 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ‐174 CC genotype
Trial: 12928051
Drug: ‐174 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ‐174 CC and VNTR DD genotypes
Trial: 6605565
Drug: Rifampin 20
RxNorm normalized name: rifampin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 20 mg/kg once daily for four days
Trial: 19743543
Drug: Ranolazine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500 mg to 1000 mg twice a day) added to ongoing amlodipine therapy
Trial: 15333452
Drug: Oral lactobacillus
RxNorm normalized name: Lactobacillus acidophilus Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lactobacillus
Trial: 8880290
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine clonixinate 4 mg x kg‐1
Trial: 8880290
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine clonixinate 6 mg x kg‐1
Trial: 30202916
Drug: Daily tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tobacco consumption (10 g/day increase)
Trial: 28477944
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (1.7 g/kg per day) during hospitalization, daily protein supplement (18.8 g), and 3 weekly resistance training sessions for 12 weeks after discharge
Trial: 25391814
Drug: Psyllium (7.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (7.0 g daily)
Trial: 16636130
Drug: r‐metHuLeptin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐metHuLeptin therapy